723 related articles for article (PubMed ID: 17194911)
1. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
Schmoll HJ; Cartwright T; Tabernero J; Nowacki MP; Figer A; Maroun J; Price T; Lim R; Van Cutsem E; Park YS; McKendrick J; Topham C; Soler-Gonzalez G; de Braud F; Hill M; Sirzén F; Haller DG
J Clin Oncol; 2007 Jan; 25(1):102-9. PubMed ID: 17194911
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
[TBL] [Abstract][Full Text] [Related]
3. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.
Díaz-Rubio E; Tabernero J; Gómez-España A; Massutí B; Sastre J; Chaves M; Abad A; Carrato A; Queralt B; Reina JJ; Maurel J; González-Flores E; Aparicio J; Rivera F; Losa F; Aranda E;
J Clin Oncol; 2007 Sep; 25(27):4224-30. PubMed ID: 17548839
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
Haller DG; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Gilberg F; Rittweger K; Schmoll HJ
J Clin Oncol; 2011 Apr; 29(11):1465-71. PubMed ID: 21383294
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
[TBL] [Abstract][Full Text] [Related]
7. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E
J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795
[TBL] [Abstract][Full Text] [Related]
8. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer.
Rödel C; Liersch T; Hermann RM; Arnold D; Reese T; Hipp M; Fürst A; Schwella N; Bieker M; Hellmich G; Ewald H; Haier J; Lordick F; Flentje M; Sülberg H; Hohenberger W; Sauer R
J Clin Oncol; 2007 Jan; 25(1):110-7. PubMed ID: 17194912
[TBL] [Abstract][Full Text] [Related]
9. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
[TBL] [Abstract][Full Text] [Related]
11. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.
Twelves CJ
Clin Colorectal Cancer; 2006 Nov; 6(4):278-87. PubMed ID: 17241512
[TBL] [Abstract][Full Text] [Related]
12. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.
Poplin EA; Benedetti JK; Estes NC; Haller DG; Mayer RJ; Goldberg RM; Weiss GR; Rivkin SE; Macdonald JS
J Clin Oncol; 2005 Mar; 23(9):1819-25. PubMed ID: 15774775
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
[TBL] [Abstract][Full Text] [Related]
14. Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: phase II clinical study (The FACOS study).
Kosugi C; Koda K; Ishibashi K; Yoshimatsu K; Tanaka S; Kato R; Kato H; Oya M; Narushima K; Mori M; Shuto K; Ishida H
Int J Colorectal Dis; 2018 Jun; 33(6):809-817. PubMed ID: 29484450
[TBL] [Abstract][Full Text] [Related]
15. Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer?
Twelves C
Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):23-6. PubMed ID: 12520636
[TBL] [Abstract][Full Text] [Related]
16. Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial.
Glen H; Cassidy J
Expert Rev Anticancer Ther; 2008 Apr; 8(4):547-51. PubMed ID: 18402521
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
Saltz LB; Niedzwiecki D; Hollis D; Goldberg RM; Hantel A; Thomas JP; Fields AL; Mayer RJ
J Clin Oncol; 2007 Aug; 25(23):3456-61. PubMed ID: 17687149
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine as adjuvant treatment for stage III colon cancer.
Twelves C; Wong A; Nowacki MP; Abt M; Burris H; Carrato A; Cassidy J; Cervantes A; Fagerberg J; Georgoulias V; Husseini F; Jodrell D; Koralewski P; Kröning H; Maroun J; Marschner N; McKendrick J; Pawlicki M; Rosso R; Schüller J; Seitz JF; Stabuc B; Tujakowski J; Van Hazel G; Zaluski J; Scheithauer W
N Engl J Med; 2005 Jun; 352(26):2696-704. PubMed ID: 15987918
[TBL] [Abstract][Full Text] [Related]
19. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
Hennig IM; Naik JD; Brown S; Szubert A; Anthoney DA; Jackson DP; Melcher AM; Crawford SM; Bradley C; Brown JM; Seymour MT
J Clin Oncol; 2008 Jul; 26(20):3411-7. PubMed ID: 18612156
[TBL] [Abstract][Full Text] [Related]
20. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
Scheithauer W; McKendrick J; Begbie S; Borner M; Burns WI; Burris HA; Cassidy J; Jodrell D; Koralewski P; Levine EL; Marschner N; Maroun J; Garcia-Alfonso P; Tujakowski J; Van Hazel G; Wong A; Zaluski J; Twelves C;
Ann Oncol; 2003 Dec; 14(12):1735-43. PubMed ID: 14630678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
